

IPR & Innovation

Doctors Without Borders urges PM Modi not to change patent rules, [Business Standard](#)

The international medical humanitarian organisation Medecins Sans Frontieres (MSF), or Doctors Without Borders, on June 12, 2015 launched a global campaign urging Prime Minister Narendra Modi to stand strong in the face of intensifying multinational pressure to change India's laws and policies that would severely restrict production of affordable medicines, upon which millions of people around the world depend, said MSF in a press release.

IPFACE, Gopakumar Nair Associates & others to organise seminar on recent developments in patent law, [Pharmabiz.com](#)

The Intellectual Property Facilitation Center (IPFACE), Venture Center & IP Group, NCL Innovations, Gnanlex Hermeneutics and Gopakumar Nair Associates to organise a one day seminar on current themes in pharma patenting with an aim to overview and insights on recent developments in patent law and practice of relevance to the pharma industry and research. The seminar will be held at Venture Center, Pune on June 20, 2015. The seminar will address various speakers Andreyra Fernandes, IP/Patent and legal associate at Gopakumar Nair Associates; Gopakumar Nair, founder, Gopakumar Nair Associates; Ashutosh Prachand, Jr. IP Associate , IP Facilitation Center at Venture Center; Nitin Tewari, scientist, IP Group and NCL Innovations; Amarendra Samal, Assistant Controller of Patents & Designs CGPDTM, Mumbai and many more. Intellectual property rights (IPR) in the pharma domain have been an argumentative issue globally. Previously, the IPR debates were typically between the branded pharma companies and generic pharma companies.

Similar reports have appeared in:

[Express Pharma](#)

India and EU to begin joint research on 'Diagnostics and interventions in chronic non-communicable diseases' [Pharmabiz.com](#)

To support high quality research, development and innovation of projects involving partners from Europe and India, India and the European Union will soon begin research on health with focus on 'Diagnostics and interventions in chronic non-communicable diseases'. The focus areas of the research will include, development of tools and technologies for the diagnostics of chronic non-communicable diseases; research and innovation within interventions for chronic non-communicable diseases; and mechanisms in chronic non-communicable diseases.

Accesses to Healthcare

Parthasarathi Shome: Supply constraints for private sector healthcare, [Business Standard](#)

Supply of healthcare in India is among the lowest in the world on a per capita basis. This is especially so as we go down the income scale, at the bottom of which there is little availability of hospitals or even health centres, doctors, nurses, or surgical and laboratory equipment. For example, World Health Organization guidelines recommend 3.5 hospital beds per 1,000 population. While the global average is 2.3 beds per 1,000 population, India is at 0.7 beds per 1,000 population.

Ethics and Compliances

Mislabelled tablet strip raises fears among people, [The Hindu](#)

The photo of a drug which is supposed to be released next year has been doing the rounds on social media for the past few days . The tablet strip's manufacturing date says April 2016 and the expiry date, March 2018. The tablet, labelled 'Flame,' has been manufactured by an Indore-based pharmaceutical company and is a combination of ibuprofen, paracetamol and caffeine. It has been priced at Rs. 11.30 per strip of 10 tablets. Drug Control authorities say they have deployed drug inspectors to procure the tablets.

“We have asked our field staff to check with wholesale stockists too. But, we have not seen the strip in any shop in Tamil Nadu. It is possible that it is not in circulation in this State,” said State Drug Controller Abdul Khader.

Medical & Regulatory

AICDF urges NPPA to initiate action against erring manufacturers, [Pharmabiz.com](#)

Coming down heavily on the National Pharmaceutical Pricing Authority (NPPA) for its lethargy to take action against violators, the All India Chemists and Distributors Federation (AICDF) has urged the national drug price regulator to initiate action against the erring manufacturing companies. According to the traders' body, several manufacturing companies are fixing two types of prices for same brand of products of one batch for the purpose of supplying to hospitals and for wholesalers. AICDF has alleged that NPPA is favouring the manufacturing industry for all their violations and destroying the trade sector. It is functioning not for helping the ailing community for whom the government is planning several health projects, but for the purpose of supporting the manufacturers make big profits, the association alleged.

Indian Pharmacist Association opposes online sale of medicines, [Express Pharma](#)

In the representation, Bhupendra Kumar, General Secretary, IPA requested the Drug Controller of the CDSCO to not to allow online pharmacy because online pharmacy will violate the various acts like Pharmacy Act, Drugs & Cosmetic Act and Violation of Human Rights. According to Pharmacy Act (An Act to regulate the profession of Pharmacy), “No person other than a registered pharmacist shall dispense any medicine on the prescription of a medical practitioner and whoever contravenes these provisions shall be punishable with imprisonment for a term which may extend to six months.

GPMA meets senior state govt officials to highlight challenges faced by pharma cos in Goa, [Pharmabiz.com](#)

Keen to address the issues faced by the pharma industry in Goa, the Goa Pharmaceuticals Manufacturers' Association (GPMA) recently met key government and regulatory officials in the state. The main agenda behind this meet was to represent the challenges faced by the pharma units in Goa for their continuance as well as for their expansion programmes. Goa currently has over 70 units operating for various markets, out of this 40 are approved by either one of the major regulatory bodies worldwide. GPMA pointed out that it is important to note that no major units have received import alerts or warning letters from US FDA, an issue plaguing the pharma industry in the rest of the country.
